Valeant Trumps Paladin In Afexa Takeover Bid

Valeant Pharmaceuticals International has agreed to acquire fellow Canadian firm Afexa Life Sciences for 76 million Canadian Dollars in cash, a figure that comfortably tops an offer made by Paladin Labs, who are also based in Canada. Over the summer, Paladin, which owns almost 15% of Afexa, had offered C$0.55 per share for the stock

Continue Reading